Compare Bristol-Myers Squibb Co (BMY) vs HCA Health Inc (HCA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs HCA Health Inc — how do they compare? Bristol-Myers Squibb Co trades at $57 (market cap $116.30B), while HCA Health Inc trades at $367 (market cap $80.66B). The key difference: Bristol-Myers Squibb Co is the larger of the two by market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BMY | HCA | |
|---|---|---|
Market Cap | $116.30B | $80.66B |
Sector | Health | Health |
52-Week High | $62.37 | $545.13 |
52-Week Low | $42.60 | $334.32 |
Enterprise Value | $152.24B | $129.57B |
Dividend Yield | 4.42% | 0.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
HCA Healthcare stock trades at $390.74, down 3.9% following a lowered 2026 profit outlook. The company maintains strong fundamentals with revenue growth to $75.6B in 2025 and consistent earnings beats, though technical indicators show bearish momentum. Recent news highlights challenges from payer mix shifts and rising uninsured patients, creating near-term headwinds despite long-term capacity expansion initiatives.
The stock presents a valuation opportunity with a P/E of 13.5x below industry averages, supported by analyst consensus target of $481.80. Key risks include execution on guidance and healthcare reimbursement pressures, but institutional sentiment remains positive with 63% buy ratings, suggesting potential recovery once near-term uncertainties resolve.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About HCA Health Inc
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.
Read more on HCA →
